MedTrace Logo

SRT Combined With Anlotinib for the Treatment of Brain Metastases From Non-small Cell Lung Cancer

NCT06476093 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2024-06-26

No results posted yet for this study

Summary

To evaluate the efficacy and safety of SRT combined with anlotinib in the treatment of limited brain metastases from non-small cell lung cancer.

Conditions

Interventions

DRUG

Anlotinib hydrochloride

Anlotinib#12mg#PO#Q3W#d1-14# SRT#depends

Sponsors & Collaborators

  • The First People's Hospital of Lianyungang

    lead OTHER

Principal Investigators

  • Xiaodong Jiang, Doc · THE FIRST PEOPLE'S HOSPITAL OF LAINYUNGANG

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-07-01
Primary Completion
2026-12-31
Completion
2027-02-28

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06476093 on ClinicalTrials.gov